Latest Conference Articles

Hasbargen presented clinical cases alongside James Del Rosso, DO, at IDS 2023.

Kwatra reviewed skin lesions in PN and important treatment considerations for patients at Fall Clinical.

Catch up on coverage from the first day of the 2023 Fall Clinical Dermatology Conference and the Inflammatory Disease Summit.

Andrea Nguyen, PA-C, reviewed types of clinical trials, phases, expenses, and more at the 2023 Inflammatory Disease Summit.

Bhatia also shared insights into ritlecitinib for alopecia areata at Fall Clinical 2023.

Lauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to AD, PsO, and HS.

Test your knowledge on the foundation leading to the development of biologics to treat atopic dermatitis.

Farberg is looking forward to another year of top-notch presentations at Fall Clinical 2023.

Cheryl Burgess, MD, will share pearls on counseling patients on appropriate cosmetic procedures for their skin type, safety measures, and strategies to achieve desired outcomes.

Looking to explore the city between Fall Clinical sessions or to extend your stay? Check out this top 10 list of the best Las Vegas has to offer in October.

One of the largest dermatology meetings of the year kicks off today with an exciting line up of expert perspectives and clinical pearls. Here's what you can expect.

Click here to answer if you're attending IDS 2023.

One of the many minds behind innovative Fall Clinical Dermatology sessions gives a sneak peek of the top 5 things to look forward to during this year's meeting.

Click here to answer if you're attending Fall Clinical.

Among the many sessions to be held at the 2023 Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Kwatra presented the abrocitinib data at EADV 2023.

The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.

After maintenance treatment with sonelokimab dosed every 4 weeks, 57% of patients achieved HiSCR75 at week 24.

Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.

The continued reduction in WI-NRS was seen in patients who remained in the study through week 52.

UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year's EADV Congress.

Sanofi’s phase 3 program for amlitelimab in atopic dermatitis will start in early 2024.

Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.

At week 8, 65.3% of roflumilast-treated patients achieved a clinically significant reduction in itch.

AbbVie announced the 24- and 52-week data at EADV 2023.

Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.

New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.

Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.